Last updated: February 20, 2026
What is the Current Status of BRUKINSA Clinical Trials?
BRUKINSA (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor developed by BeiGene for hematologic malignancies. Since its FDA approval in November 2019 for mantle cell lymphoma (MCL), the drug has undergone multiple clinical trials across various blood cancers.
Key Clinical Trials
| Trial Name |
Phase |
Indication |
Enrollment |
Outcome Highlights |
Status |
| BGB-3111-2101 |
Phase III |
Waldenström's Macroglobulinemia (WM) |
128 |
Non-inferior to ibrutinib, with fewer atrial fibrillation cases |
Ongoing |
| ALPINE (NCT03734016) |
Phase III |
Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
580 |
Superior to ibrutinib in progression-free survival (PFS); fewer adverse events |
Completed |
| Wizard |
Phase III |
Relapsed/Refractory MCL |
86 |
Superior response rate, fewer severe adverse events |
Completed |
| AUGMENT (NCT03112174) |
Phase III |
Waldenström's Macroglobulinemia |
150 |
Demonstrated durable responses; safety profile consistent |
Ongoing |
Regulatory Progress
- Approved in the U.S. for MCL (2019) via accelerated approval based on objective response rate.
- Approved in China (2022), with ongoing applications elsewhere.
- Fast-track designations granted for WM and CLL in the U.S.
Market Analysis for BRUKINSA
Market Size and Growth Drivers
The global hematologic malignancies market was valued at USD 9.5 billion in 2022 and is projected to reach USD 14.2 billion by 2030, at a CAGR of 5.2% [1].
Key growth drivers include:
- Rising incidence of MCL, CLL, and WM
- Shift toward oral targeted therapies
- Increasing adoption of BTK inhibitors
Competitive Landscape
Major competitors:
| Drug |
Company |
Indication |
Market Share (2022) |
US Launch Year |
| BRUKINSA |
BeiGene |
MCL, WM, CLL |
22% |
2019 |
| Imbruvica (ibrutinib) |
Pharmacyclics/Janssen |
Multiple |
50% |
2013 |
| Venclexta (venetoclax) |
AbbVie |
CLL, AML |
14% |
2016 |
BRUKINSA accounts for a growing segment, especially among patients with cardiac comorbidities, due to its lower atrial fibrillation incidence compared to ibrutinib.
Pricing and Reimbursement
In the U.S., the average wholesale price (AWP) is approximately USD 16,776 per 30-day supply [2]. Insurance coverage and reimbursement policies influence market penetration in different regions.
Market Projection and Future Opportunities
Sales Forecast (2023–2030)
| Year |
Estimated Global Sales (USD Billion) |
Source |
| 2023 |
1.2 |
Analyst estimates |
| 2025 |
2.4 |
Market research reports |
| 2030 |
3.5 |
Targeted market penetration |
Growth is driven by expanded indications, including first-line therapy for CLL/SLL, and potential approvals for additional hematologic cancers such as Waldenström's macroglobulinemia and marginal zone lymphoma.
Pipeline and Development Opportunities
- Trials underway for combination regimens with venetoclax and anti-CD20 therapies.
- Exploring use in solid tumors with BTK expression.
- Potential in autoimmune diseases due to BTK's role in B-cell activation.
Regulatory and Patent Outlook
- Continued regulatory submissions anticipated in Europe and Asia.
- Patent protections extend until approximately 2030; potential generics may influence pricing.
Key Takeaways
BRUKINSA demonstrates promising clinical efficacy and a favorable safety profile in multiple hematologic malignancies, supported by robust trial data. Market growth is concentrated on its differentiated profile from competitors, especially in patient subsets with cardiac risks. Sales are expected to increase with expanded indications and geographic expansion.
FAQs
1. How does BRUKINSA differ from ibrutinib?
BRUKINSA has fewer off-target effects, leading to a lower incidence of adverse events like atrial fibrillation, making it suitable for patients with cardiovascular comorbidities.
2. What are the main indications for BRUKINSA?
It is approved for mantle cell lymphoma, Waldenström’s macroglobulinemia, and chronic lymphocytic leukemia.
3. What are the primary trial results supporting BRUKINSA’s efficacy?
Clinical trials demonstrate non-inferiority or superiority to existing therapies like ibrutinib, with durable responses and fewer severe adverse events.
4. What market factors influence BRUKINSA’s adoption?
Pricing, reimbursement policies, physician preference for oral targeted therapies, and competitive landscape all impact its market penetration.
5. What are the future development prospects for BRUKINSA?
Expanded indications, new combination therapies, and potentially broader applications in autoimmune diseases are under investigation.
References:
[1] Market Research Future. (2023). Hematologic Malignancies Market Analysis.
[2] Medicare.gov. (2023). Part D Prescription Drug Pricing Data.
